Puma Biotechnology | PBYI - Процентные расходы





Процентные расходы Изменить Дата
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Daiichi Sankyo JPY 3.57B 1.4B 2026-03
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 247M 7M 2026-06
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Incyte USD 582K 13K 2026-06
MacroGenics USD 4.89M 1.55M 2026-03
Moderna USD 10.96B 527M 2026-06
Novartis USD 462M 119M 2026-06
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Takeda JPY 63.85B 20.2B 2026-06
TG Therapeutics USD 16.57M 8.91M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12